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Abstract
 
Prediabetes and diabetes in nonobese diabetic (NOD) mice have been targeted by a variety of
immunotherapies, including the use of a soluble form of cytotoxic T lymphocyte antigen 4
(CTLA-4) and interferon (IFN)-
 
 
 
. The cytokine, however, fails to activate tolerogenic properties
in dendritic cells (DCs) from highly susceptible female mice early in prediabetes. The defect is
characterized by impaired induction of immunosuppressive tryptophan catabolism, is related to
transient blockade of the signal transducer and activator of transcription (STAT)1 pathway of
intracellular signaling by IFN-
 
 
 
, and is caused by peroxynitrite production. Here, we show that
soluble CTLA-4 imparts suppressive properties to DCs from early prediabetic NOD female mice
through mechanisms that rely on autocrine signaling by IFN-
 
 
 
. Although phosphorylation of
STAT1 in response to IFN-
 
  
 
is compromised in those mice, CTLA-4 obviates the defect.
IFN-
 
 
 
–driven expression of tryptophan catabolism by CTLA-4–immunoglobulin is made possible
through the concomitant activation of the Forkhead Box class O (FOXO) transcription factor
FOXO3a, induction of the superoxide dismutase gene, and prevention of peroxynitrite formation.
Key words: NOD mice • dendritic cells • CTLA-4 • superoxide dismutase • 
signal transduction
 
Introduction
 
The nonobese diabetic (NOD) strain of mice has become a
prototypic model of autoimmune disease (1). Most female
mice die of type 1 diabetes, reflecting the onset of insulitis
at 
 
 
 
4 wk of age and the T cell–mediated destruction of
pancreatic 
 
  
 
cells. Several defects have been described in
NOD mice, including impaired expression of cytotoxic T
lymphocyte antigen 4 (CTLA-4; reference 2), aberrant
APC function (3), and peroxynitrite formation (4). Predia-
betes and diabetes have been treated with age-related out-
comes by numerous, apparently disparate approaches, in-
cluding administration of soluble CTLA-4 (CTLA-4–Ig;
reference 5) and the use of IFN-
 
  
 
(6, 7).
We have recently proposed a model of tolerance induction
that might trace the activity of the synthetic immunomodula-
tor CTLA-4–Ig (8), CTLA-4–expressing regulatory T cells
(9), and recombinant IFN-
 
  
 
(10) to a unitary mechanism. In
this model, CTLA-4–Ig acts through B7-mediated signaling
in tolerogenic DCs to promote release of IFN-
 
 
 
, whose au-
tocrine effects result in activation of the immunosuppressive
pathway of tryptophan catabolism (11). However, IFN-
 
  
 
is
unable to induce tolerizing properties in DCs from NOD
female mice at 4 wk of age, and this is apparently due to per-
oxynitrite nitration of STAT1 and blockade of IFN-
 
  
 
signal-
ing (12). The enzyme indoleamine 2,3-dioxygenase (IDO) is
in fact responsible for tryptophan degradation by DCs (11),
and IDO induction by IFN-
 
  
 
requires STAT1 signaling (8).
Transcription factors of the Forkhead Box class O (FOXO)
family are known to act as signal transducers at the conflu-
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ence of multiple signaling pathways (13). For example,
they represent important downstream targets of the phos-
phatidylinositol 3 kinase (PI3K) pathway, which has been
shown to play a critical role in cell proliferation and sur-
vival (14). FOXO factors function under the control of in-
sulin/insulin-like signaling (15). Through the involvement
of FOXO family members, insulin regulates hepatic glu-
coneogenesis (16, 17) and reduces expression of pyruvate
dehydrogenase kinase 4 activity, which is increased by glu-
cocorticoids and diabetes (18). A member of the FOXO
family protects quiescent cells from oxidative stress (19).
In this study, we provide evidence that CTLA-4–Ig can
bypass the DC defect in tolerogenesis of prediabetic mice,
enabling IFN-
 
  
 
responsiveness and tryptophan catabolism
to occur. The activity of CTLA-4–Ig relies on activation of
members of the FOXO family of transcription factors, in-
duction of superoxide dismutase (SOD), and blockade of
peroxynitrite formation. Thus, composite mechanisms con-
tribute to the therapeutic efficacy of CTLA-4–Ig in auto-
immune diabetes in NOD mice. Although damage from
oxidative stress can compromise early tolerogenesis in these
animals, the immunosuppressive activity of DCs can be
fully rescued by coordinate actions of CTLA-4–Ig on cyto-
kine production and the oxidant/antioxidant balance.
 
Materials and Methods
 
Mice and Reagents.
 
Female and male NOD/LtJ mice, 4 and 8
wk of age, were purchased from The Jackson Laboratory. NOD
female mice genetically deficient in IFN-
 
  
 
(NOD.
 
IFN-
 
 
 
null
 
; ref-
erence 20) or the 
 
  
 
chain subunit of IFN-
 
  
 
receptor (NOD.
 
IFN-
 
 
 
RB
 
null
 
; reference 21) were as described previously. The enzyme
inhibitors 1-methyl-
 
dl
 
-tryptophan (1-MT; Sigma-Aldrich), guani-
dinoethyl disulphide (GED; Sigma-Aldrich), 2-methoxyestradiol
(2-MeOE
 
2
 
; Calbiochem), and LY294002 (Cell Signaling Tech-
nology) were commercially available products. The SOD mi-
metic agent Mn(III)tetrakis(4-benzoic acid)porphyrin chloride
(MnTBAP) was from Calbiochem. LY294002 is a specific inhib-
itor for PI3Ks, and at a concentration of 50 
 
 
 
M, it has no inhibi-
tory effect on a range of protein kinases, including the c-AMP–
dependent protein kinase and 
 
c
 
-Src (22, 23). For 2-MeOE
 
2
 
, a
SOD inhibitor, previous studies have demonstrated that the
agent, when used at concentrations up to 100 
 
 
 
M, has limited or
no effects on a variety of enzymatic functions, indicating that in-
hibition of SOD by 2-MeOE
 
2 
 
is probably specific (24). The
pharmacological characterization and selectivity of GED as an in-
hibitor of nitric oxide (NO) synthase have been described previ-
ously (25). The issue of selectivity of 1-MT in inhibiting IDO has
thoroughly been discussed elsewhere (26). All in vivo studies
were performed in compliance with National and Perugia Uni-
versity Animal Care and Use Committee guidelines.
 
DC Preparations and Treatments and Immunization.
 
Splenic
DCs were prepared from pools of at least five mice and fraction-
ated according to CD11c/CD8
 
  
 
expression using positive selec-
tion columns in combination with CD11c and CD8
 
  
 
micro-
beads (10, 12, 27). For cytokine activation (27), DCs were
subjected to overnight exposure to 100 ng/ml rIL-12 (CD8
 
 
 
DCs) or 200 U/ml IFN-
 
  
 
(CD8
 
  
 
DCs) in the presence or ab-
sence of 2 
 
 
 
M 1-MT, 250 
 
 
 
M GED, or 25 
 
 
 
M LY294002.
Cells were instead exposed to 100 
 
 
 
M MnTBAP for 5 h before
the addition of IFN-
 
 
 
. CD8
 
  
 
DC activation with CTLA-4–Ig
involved exposure to 40 
 
 
 
g/ml of the synthetic immunomodula-
tor with or without 2 
 
 
 
M 1-MT or 10 
 
 
 
g/ml XMG1.2-neutral-
izing anti–IFN-
 
  
 
antibody (9). Cells were exposed to 2 
 
 
 
M
2-MeOE
 
2 
 
for 5 h before the addition of CTLA-4–Ig. 40 
 
 
 
g/ml
of native IgG3 was always used as a control in all experiments in-
volving CTLA-4–Ig (8). In all treatments involving CTLA-4–Ig,
IFN-
 
 
 
, MnTBAP, or enzyme inhibitors, either singly or in com-
bination, cell viability remained 
 
 
 
70% at the end of the incuba-
tion period. For immunization, cells were washed before peptide
loading (5 
 
 
 
M for 2 h at 37
 
 
 
C), irradiation, and i.v. injection into
recipient hosts. 3 
 
  
 
10
 
5 
 
IL-12–treated CD8
 
  
 
DCs were injected
in combination with 9 
 
  
 
10
 
3 
 
CD8
 
  
 
DCs either as such or treated
with different agents as indicated above.
 
Skin Test Assay.
 
A skin test assay was used for measuring class
I–restricted delayed-type hypersensitivity responses to the syn-
thetic NRP-A7 peptide, as described previously (9, 10), using
4-wk-old NOD female mice as recipients. Results were expressed
as the increase in footpad weight of peptide-injected footpads over
that of vehicle-injected counterparts, which served as an internal
control for each individual animal. Data are the mean 
 
  
 
SD for at
least six mice per group. The statistical analysis was performed us-
ing Student’s paired 
 
t
 
 test by comparing the mean weight of ex-
perimental footpads with that of control counterparts. The mean
weight of control (vehicle-injected) footpads was in the 130–150
mg range, depending on individual experiments. In a given exper-
iment, the different treatments of mice with DCs would not
change per se the actual weights of control footpads.
 
Kynurenine Assay.
 
IDO functional activity was measured in
vitro in terms of ability of DCs to metabolize tryptophan to
kynurenine, whose concentrations were measured by HPLC as
described previously (28).
 
Western Blot Analyses.
 
IDO expression was investigated as de-
scribed previously (9) using a specific antibody in CD8
 
  
 
DCs either
untreated or exposed overnight to 200 U/ml IFN-
 
 
 
, with or with-
out MnTBAP, or to 40 
 
 
 
g/ml CTLA-4–Ig. On studying STAT1
phosphorylation, CD8
 
  
 
DCs were exposed for 5 h to MnTBAP,
and then treated with 200 U/ml IFN-
 
  
 
for 10 min. After SDS-
PAGE resolution, immunoblotting was performed by sequential
exposure to anti-phosphoSTAT1 and anti-STAT1 antibodies
(both from Cell Signaling Technology). For analysis of SOD ex-
pression, cells either untreated or treated overnight with CTLA-4–
Ig were subjected to Western blot by means of an anti-MnSOD
(SOD-111) or an anti-Cu/ZnSOD (SOD-101) rabbit polyclonal
antibody specific for SOD2 and SOD1, respectively (Stressgen
Biotechnology). Analysis of FOXO protein expressions in cyto-
solic (29) and nuclear (30) extracts of CD8
 
  
 
DCs treated overnight
with CTLA-4–Ig involved the use of rabbit polyclonal anti-
FKHRL1 (FOXO3a) antibody (Upstate Biotechnology) according
to manufacturer’s instructions. For immunoprecipitation of NIH/
3T3 cells, an anti-FKHRL1 antibody (Santa Cruz Biotechnology,
Inc.) and a control rabbit polyclonal antibody were used. Anti-
aldolase and anti-lamin A/C antibody reagents were from Santa
Cruz Biotechnology, Inc. Anti–phospho-FKHRL1 (Thr32) was
also from Upstate Biotechnology. Anti–human PTEN (clone
6H2.1), cross-reactive with its murine counterpart, was from Cas-
cade Bioscience. Rabbit polyclonal anti-AKT and anti–phospho-
AKT reagents were from Cell Signaling Technology.
 
Nitrotyrosine ELISA and Intracellular Superoxide Assessment.
 
The former assay was performed using a Nitrotyrosine ELISA kit
(HyCult Biotechnology b.v.) according to the manufacturer’s in-
structions (12). The latter is based on the chemical properties of
hydroethidine, a weak blue fluorescent dye that is selectively con- 
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verted by superoxide anion to ethidium with a bright red fluores-
cence (31). The control and drug-treated cells (1.5 
 
  
 
10
 
6
 
/sample)
were incubated with 20 ng/ml hydroethidine for 30 min, washed,
and analyzed by flow cytometry using the red laser channel.
 
Luciferase Assay.
 
6 
 
  
 
10
 
6 
 
DCs were electroporated (230 V,
75 ohms, 1,500 microfarads) with 40 
 
 
 
g FHRE-Luc plasmid.
The construct contains three FKHRL1 elements from the human
Fas ligand promoter (32) and was provided by M.E. Greenberg
(Harvard Medical School, Boston, MA). 1 
 
 
 
g of another reporter
plasmid, pRL-TK (Promega) encoding 
 
renilla
 
 luciferase, was co-
electroporated as an internal control of the transfection process.
Cells were seeded in 48-well plates at 10
 
6
 
/ml. The next day, cells
were stimulated for 6 or 24 h with CTLA-4–Ig or LY294002 be-
fore lysis. Luciferase assays were performed using a dual luciferase
reporter assay kit (Promega). Relative light units (RLUs) from
the firefly luciferase were normalized for transfection efficiency to
the 
 
renilla
 
 luciferase RLU in each lysate. The 
 
renilla
 
 luciferase
RLU values in 40-
 
 
 
l lysates were in the same range (0.224–
0.256, typically in one experiment at 24 h) for control, CTLA-4–
Ig, or LY294002 treatments of DCs either as such or subjected to
gene silencing.
 
Small Interfering RNA (siRNA) Synthesis and Transfection.
 
The
siRNA sequences specific for murine FOXO3 (sense, 5
 
 
 
-GCU-
CCUCACUGUAUUCAGtt-3
 
 
 
; antisense, 5
 
 
 
-CUGAAUACA-
GUGAGGAGCCtg-3
 
 
 
) were selected, synthesized, and annealed
by the manufacturer (Ambion). For transfection, 6.7 
 
 
 
g siRNA
in 30 
 
 
 
l of transfection buffer (20 mM Hepes, 150 mM NaCl,
pH 7.4) were pipetted into a sterile eppendorf tube. In a separate
polystyrene tube, 6.7 
 
 
 
g DOTAP (1,2 dioleoyl-3-trimethylam-
monium-propane) was mixed with 30 
 
 
 
l of transfection buffer,
and then both solutions were mixed gently by pipetting several
times. After incubation at room temperature for 20 min, the
mixture was added to 1 ml of complete medium containing 10
 
6
 
DCs and incubated for 20 h at 37
 
 
 
C. Cells were then recov-
ered, washed, and immediately used for in vitro or in vivo
experiments.
 
Results
 
A SOD Mimetic Restores IFN-
 
  
 
Responsiveness in DCs
from 4-wk-old NOD Female Mice.
 
The tolerogenic poten-
tial of IFN-
 
  
 
is specifically lost in CD8
 
  
 
DCs from early
prediabetic NOD female mice, in which peroxynitrite-
mediated nitration of STAT1 is observed (12). Peroxynitrite
is a highly reactive oxidant resulting from the interaction of
NO with superoxide. SOD can scavenge superoxide and
thus limit peroxynitrite formation. MnTBAP is a synthetic
mimetic of SOD that does not scavenge NO. Because of
the ability of the inhibitor of NO synthase and direct scav-
enger of peroxynitrite, GED, to restore IFN-
 
  
 
responsive-
ness in vitro in CD8
 
  
 
DCs from 4-wk-old NOD female
mice (12), we comparatively analyzed the effect of GED
and MnTBAP on the in vivo ability of those cells to mod-
ulate CD8
 
  
 
DC priming to NRP-A7, a peptide mimotope
for autoimmune diabetes in mice (33, 34). A combination
of immunogenic CD8
 
  
 
and tolerogenic CD8
 
  
 
DCs were
injected into NOD mice that were assayed at 2 wk for skin
test reactivity to the eliciting peptide. DCs from 4-wk-old
NOD female mice were thus fractionated, treated with cy-
tokines, loaded with the peptide, and injected into recipi-
ent hosts. IL-12 was used to enhance the priming ability of
CD8
 
  
 
DCs (35) and IFN-
 
  was used to induce tolerizing
properties in CD8  DCs (10). Groups of CD8  DCs were
treated with IFN-  in the presence of GED or MnTBAP,
with or without 1-MT, which is a competitive inhibitor of
IDO (Fig. 1). As expected, IFN-   treatment alone of
CD8  DCs did not enable these cells to prevent host
priming to NRP-A7. However, the presence of GED or
MnTBAP during IFN-  activation rescued the ability of
CD8  DCs to suppress immunity. The effect was depen-
dent on tryptophan catabolism, as it was negated by the
addition of 1-MT to the combination of IFN-  and GED
or MnTBAP. No effect was afforded by the use of GED or
MnTBAP in the absence of IFN- , further indicating that
the latter is required for the induction of tolerance in this
experimental setting.
To confirm that the mechanism of action of MnTBAP
involved the rescue of IFN-  signaling through STAT1 and
enhanced transcription of the IDO gene, we analyzed
STAT1 phosphorylation and IDO protein expression by
Western blot in CD8  DCs (Fig. 2 A). At the same time,
we measured IDO functional activity in terms of ability to
metabolize tryptophan to kynurenine in vitro (Fig. 2 B).
CD8  DCs from 8-wk-old NOD female mice were used as
a control in both assays. Similar to GED (12), MnTBAP re-
stored, at least in part, STAT1 phosphorylation and IDO
protein expression as well as kynurenine production in DCs
from 4-wk-old NOD female mice treated with IFN- .
CTLA-4–Ig Acts through Autocrine IFN-  to Obviate the
Tolerogenic Defect in 4-wk-old NOD Female Mice. The abil-
ity of CTLA-4–Ig to prime DCs from conventional strains
of mice for tolerogenic, IDO-dependent effects requires au-
Figure 1. Ability of the SOD mimetic MnTBAP to activate IDO-
dependent  tolerizing properties in CD8  DCs from early prediabetic
NOD female mice. Combinations of IL-12–treated CD8  and CD8 
DCs subjected to various treatments (indicated) were loaded with NRP-A7
and injected into recipient mice to be assayed at 2 wk for skin test reactivity
to the eliciting peptide. CD8  DCs were used after overnight activation
with 100 ng/ml IL-12, whereas CD8  DCs were used either as such or
after activation with 200 U/ml IFN-  in the presence or absence of 250
 M GED or 100  M MnTBAP. Groups of CD8  DCs were also treated
with 2  M 1-MT. *, P   0.001, experimental versus control footpads.
One experiment is reported representative of three.CTLA-4–Ig Induces FOXO-dependent Transcription in NOD Mice 1054
tocrine IFN-  and STAT1-mediated signaling (8, 9, 36).
Therefore, we investigated whether CTLA-4–Ig would be
able to rescue the tolerizing ability of CD8  DCs from
4-wk-old NOD female mice. We adopted an experimental
model analogous to that shown in Fig. 1, in which a combi-
nation of CD8  and CD8  DCs was injected into NOD
mice to be assayed at 2 wk for skin test reactivity to NRP-
A7. DCs from 4-wk-old NOD female mice were fraction-
ated, treated with IL-12 (CD8 ) or IFN-  (CD8 ), loaded
with the peptide, and injected into recipient hosts. In an al-
ternative to IFN- , CD8  DCs were treated with CTLA-
4–Ig. Groups of CD8  DCs were coexposed to 1-MT
or neutralizing antibody to IFN-  during activation with
CTLA-4–Ig. In addition, prediabetic NOD female mice ge-
netically deficient in IFN-  or IFN-  receptor   chain ex-
pression were used as a source of CD8  DCs to be used in
the skin test as well as kynurenine production assays. As ex-
pected, IFN-  treatment of CD8  DCs from NOD mice
did not enable these cells to prevent priming to NRP-A7
Figure 2. Ability of MnTBAP to restore IFN-   responsiveness in
CD8  DCs from early prediabetic NOD female mice. (A) MnTBAP was
examined for ability to restore STAT1 phosphorylation and IDO expression
in response to IFN- . CD8  DCs from 4-wk-old or control 8-wk-old
NOD female mice were treated with IFN-  as specified in Materials and
Methods and assayed by Western blot. IDO expression was investigated
with an IDO-specific polyclonal antibody, whereas STAT1 phosphoryla-
tion was analyzed with an anti-phosphoSTAT1 reagent. One experiment
representative of three is shown. (B) MnTBAP was also studied for its
ability to restore tryptophan conversion to kynurenine in response to
IFN- , using CD8  DCs from the same donors. Kynurenine levels in su-
pernatants were measured by HPLC, and results are the mean   SD of
triplicate samples in one of three experiments.
Figure 3. Ability of CTLA-4–Ig to rescue the tolerizing properties of
CD8  DCs from early prediabetic NOD female mice through mecha-
nisms dependent on IFN-  and IDO. (A) Mixtures of CD8  and CD8 
DCs were loaded with NRP-A7 and injected into recipient mice that
were later assayed for skin test reactivity to the peptide. CD8  DCs were
used after activation with IL-12, whereas CD8  DCs were exposed over-
night to IFN-  or CTLA-4–Ig. Groups of CD8  DCs were also treated
with 1-MT or anti–IFN-  (indicated). Mice deficient in IFN-  or IFN- 
receptor   chain were also used as a source of CD8  DCs. *, P   0.001,
experimental versus control footpads. One experiment is reported repre-
sentative of three. (B) CTLA-4–Ig was examined for its ability to initiate
tryptophan catabolism in CD8  DCs from the same donors as in A. Cells
were exposed overnight to CTLA-4–Ig in the presence or absence of
anti–IFN- , and kynurenine levels were measured in supernatants. *, P  
0.001, presence versus absence of anti–IFN-  during CTLA-4–Ig expo-
sure. One experiment representative of three is shown. (C) CTLA-4–Ig
fails to induce STAT1 phosphorylation in NOD mice deficient in IFN- 
receptor   chain. CD8  DCs, treated overnight with CTLA-4–Ig, were
assayed for STAT1 phosphorylation by Western blot analysis. One of two
experiments with similar results is shown.Fallarino et al. 1055
(Fig. 3 A). In contrast, CTLA-4–Ig was fully capable of
blocking induction of immunity. However, the copresence
of 1-MT or anti–IFN-   during CD8  cell exposure to
CTLA-4–Ig ablated the ability of the latter to prevent prim-
ing. Similar to the effect of 1-MT or anti–IFN- , the ge-
netic deficiency of IFN-   or IFN-   receptor expression
prevented CTLA-4–Ig effects on CD8  DCs. In addition,
CTLA-4–Ig initiated IFN- –dependent tryptophan catabo-
lism in vitro in CD8  DCs from 4-wk-old NOD female
mice (Fig. 3 B) and induced STAT1 phosphorylation in the
same cells (Fig. 3 C). However, no STAT1 phosphorylation
was observed in response to IFN-  when mice genetically
deficient in IFN-   receptor expression were used as a
source of DCs (Fig. 3 C). The levels of IFN-  induced by
CTLA-4–Ig in vitro in CD8  DCs from NOD mice,
whether or not deficient in IFN-   receptor expression,
were similar to those in conventional strains of mice
(unpublished data). These data might imply that although
CTLA-4–Ig induces IFN-  and this, in turn, will cause per-
oxynitrite formation (12), the fusion protein also activates
mechanisms capable of opposing peroxynitrite toxicity.
Both MnTBAP and CTLA-4–Ig Oppose Induction of Per-
oxynitrite by IFN-  in Early Prediabetic NOD Female Mice.
Peroxynitrite is produced in acutely diabetic NOD mice
(4) and may impair cell signaling via nitration of tyrosine
residues (37). We have previously shown that IFN-  will
induce high levels of peroxynitrite in CD8  DCs from
NOD females selectively at  4 wk of age (12). To investi-
gate the effects of MnTBAP and CTLA-4–Ig on peroxyni-
trite production, we analyzed IFN- –induced production
of nitrotyrosine in CD8  DCs from 4-wk-old NOD fe-
male mice. Cells were either treated with MnTBAP during
IFN-  exposure or pretreated overnight with CTLA-4–Ig
before IFN-  treatment (Fig. 4). In line with previous re-
sults (12), no nitrotyrosine formation was observed in cell
supernatants of DCs unexposed to IFN- . The cytokine
induced high levels of peroxynitrite, but this effect was
greatly impaired by the use of MnTBAP or CTLA-4–Ig.
A Specific SOD Inhibitor Blocks CTLA-4–Ig Effects on
CD8  DCs. 2-MeOE2 is an estrogen metabolite that has
been shown to inhibit SOD activity and is capable of in
vivo effects that can be traced to this property (24, 31). We
became interested in ascertaining the effect of 2-MeOE2 on
the ability of CTLA-4–Ig to rescue IDO-dependent func-
tions in CD8  DCs from 4-wk-old NOD female mice.
Cells were exposed sequentially to 2-MeOE2 and CTLA-
4–Ig to be assayed for nitrotyrosine formation in superna-
tants, functional activity in a skin test assay with the NRP-
A7 peptide, and tryptophan conversion to kynurenine (Fig.
5). In all three assays, the use of 2-MeOE2 was found to af-
fect the activity of CTLA-4–Ig, resulting in enhanced pro-
duction of nitrotyrosine in vitro, ablation of the tolerogenic
potential of the CD8  DC subset in vivo, and reduced
tryptophan conversion to kynurenine.
CTLA-4–Ig Induces SOD2 Expression and Activity in
CD8  DCs. In general, cells scavenge superoxide with
the help of an inducible MnSOD (SOD2) as well as a con-
stitutive Cu/ZnSOD (SOD1). To gain insight into the
mechanistic basis for the SOD-dependent effects of CTLA-
4–Ig on CD8  DCs from prediabetic mice, we analyzed
IDO, SOD1, and SOD2 expression by Western blot using
Figure 4. Antagonistic effect of MnTBAP and CTLA-4–Ig on induc-
tion of peroxynitrite by IFN-   in CD8  DCs from early prediabetic
NOD female mice. CD8  DCs were recovered from these animals to be
incubated overnight with IFN- . Groups of cells were cotreated with
MnTBAP or pretreated with CTLA-4–Ig before exposure to IFN- . Nitro-
tyrosine in cell supernatants was assayed by sandwich ELISA, the lower
detection limit of the assay being 2 nM. Data are means   SD of replicate
samples in one of three experiments. *, P   0.001, combined treatment
with MnTBAP or CTLA-4–Ig versus IFN-  alone.
Figure 5. Antagonistic effect of 2-MeOE2 on CTLA-4–Ig
activity. Early prediabetic NOD female mice were used as
a source of CD8  DCs that were exposed to 2-MeOE2 for
5 h before overnight incubation with CTLA-4–Ig. Nitro-
tyrosine in cell supernatants was assayed by ELISA or cells
were tested in a kynurenine production assay of IDO func-
tional activity, according to conditions specified above. Al-
ternatively, the CD8  DCs were loaded with NRP-A7,
admixed with IL-12–treated and peptide-loaded CD8  DCs,
and used in a skin test assay. *, P   0.001, presence versus
absence of 2MeOE2 during CTLA-4–Ig treatment; **, P  
0.001, experimental versus control footpads. One experi-
ment representative of three is shown.CTLA-4–Ig Induces FOXO-dependent Transcription in NOD Mice 1056
specific antibodies (Fig. 6 A). On comparing female and
male mice of 4 or 8 wk of age, we found a selective defect
in basal SOD2 protein expression in female mice at 4 wk.
However, overnight exposure to CTLA-4–Ig increased
protein expression to an extent comparable to the basal lev-
els in age-matched male and 8-wk-old female mice, in
which no major changes were induced by CTLA-4–Ig. At
the same time, CTLA-4–Ig led to comparable IDO protein
expression in the three groups of animals. In contrast,
CTLA-4–Ig had no major effect on the expression of
SOD1, which did not vary in NOD mice as a function of
age or gender.
SOD enzymes are critical in eliminating the superoxide
radical. To confirm that CTLA-4–Ig induced increased
SOD2 function, we used hydroethidine, a compound
specifically converted by superoxide to highly fluorescent
ethidium, allowing measurement of cellular superoxide
contents by flow cytometry. Using CD8  DCs from early
prediabetic female mice, we found that cell treatment with
IFN-  greatly increased superoxide levels, an effect that
was reversed by cell exposure to CTLA-4–Ig before IFN- 
treatment (Fig. 6 B).
CTLA-4–Ig Modulates FOXO Expression and Activates
FOXO-dependent Transcription and Suppressive Activity in
DCs. Recent evidence indicates that FOXO-regulated
genes include the SOD2 gene, thus revealing a role for
FOXO transcription factors, in particular FOXO3a, in the
control of oxidative stress (19). We examined whether
CTLA-4–Ig treatment of CD8   DCs from prediabetic
NOD mice affects FOXO3a expression. Using Western
blot analysis, we analyzed the pattern of expression of
FOXO3a in the cytoplasm and the nucleus (Fig. 7 A). The
experimental design included the use of controls for quality
of fractionation as well as the analysis of an immunoprecip-
itate from a reference cell line as obtained with a FOXO3a-
specific antibody. CTLA-4–Ig caused an increased level of
FOXO3a in the cytoplasm at 2 h, followed by a substantial
decline at 6–24 h. This was associated with the appearance
at 6 h of FOXO3a in the nucleus, which was followed by
an increase at 24 h.
PI3K-regulated phosphorylation of FOXO transcription
factors is pivotal in modulating their functional activity. In
the absence of phosphorylation, these factors localize in
the nucleus where they act as potent activators of tran-
scription (13–15). To confirm that FOXO factors were
among the transcriptional mediators of CTLA-4–Ig effects
in CD8  DCs from prediabetic NOD mice, we used
promoter-driven expression of luciferase activity in DCs
transfected with a reporter plasmid containing the luciferase
gene in combination with a FOXO3a-regulated promoter.
We electroporated CD8  DCs from 4-wk-old NOD fe-
male mice with the FHRE-Luc reporter plasmid regulated
by three FKHRL1 elements from the human Fas ligand
promoter. Cells were treated with CTLA-4–Ig or the
PI3K inhibitor, LY294002 (Fig. 7 B). The results showed
that both CTLA-4–Ig and the PI3K inhibitor induced an
 2.5-fold increase in the expression of luciferase activity
controlled by the FOXO-regulated promoter at  24 h of
treatment.
RNA interference is a mechanism of posttranscriptional
gene silencing that can be used for immune modulation in
DC gene expression (38). RNA interference has experimen-
tally been used for silencing genes coding for transcription
Figure 6. Ability of CTLA-4–Ig to restore SOD2 expression and func-
tion in CD8  DCs from 4-wk-old NOD female mice. (A) CTLA-4–Ig
induces SOD2 and IDO expression. Cells from different types of donor
(indicated) were treated overnight with CTLA-4–Ig to be assayed by
Western blot. IDO expression was investigated with an IDO-specific
polyclonal antibody, whereas SOD2 and SOD1 were analyzed with spe-
cific antibody reagents. Loading controls consisted of samples reprobed
with   actin–specific antibody. One experiment representative of three is
shown. (B) Superoxide accumulation in CD8  DCs treated with IFN- 
and reversal of the effect by CTLA-4–Ig. Cells were assayed for intracellular
superoxide content by flow cytometry after treatment with IFN-  or se-
quential exposure to CTLA-4–Ig and IFN-  (indicated). Cells treated
with CTLA-4–Ig alone were also assayed along with cells exposed to
200  M of a nonspecific inducer of superoxide, H2O2. Control cells (un-
treated) were freshly harvested DCs. Mean channel fluorescence intensity
values are also indicated. One of two experiments is shown.Fallarino et al. 1057
factors in human DCs (39). Therefore, we became inter-
ested in ascertaining the effects of CTLA-4–Ig in siRNA-
FOXO3a–treated DCs. We used promoter-driven expres-
sion of luciferase activity under the conditions described
above. Fig. 7 B shows that siRNA-FOXO3a completely
abolished the expression of FOXO-regulated luciferase ac-
tivity induced by CTLA-4–Ig at 24 h of treatment.
To directly investigate the effects of FOXO3a gene si-
lencing in the modulation of DC function by CTLA-4–Ig,
we measured IDO functional activity in vitro and tolero-
genic potential in vivo in CD8  DCs from 4-wk-old NOD
female mice treated or not with siRNA-FOXO3a before
CTLA-4–Ig activation. Fig. 7 C shows that FOXO3a gene
silencing abolished the ability of CD8  DCs to metabolize
tryptophan to kynurenine in response to CTLA-4–Ig. At
the same time, the siRNA-treated DCs could not be
primed by CTLA-4–Ig for suppression of footpad reactivity
to NRP when a combination of CD8  and CD8  DCs was
injected into NOD recipient mice according to the experi-
mental design shown in Fig. 1 (Fig. 7 D).
Combined Effects of IFN-  and LY294002 on Functional
Activity of CD8  DCs. The ability of the PI3K inhibitor to
activate FOXO-dependent gene transcription prompted us
to evaluate the possibility that a mixture of IFN-   and
LY294002 could affect the functional activity of CD8  DCs
from prediabetic NOD females in a manner comparable to
CTLA-4–Ig, which apparently combines the effects of both
agents. CD8  DCs from 4-wk-old animals were exposed
overnight to LY294002 and IFN-  to be assayed for interfer-
ence with the induction of immunity by cotransferred CD8 
DCs in a skin test assay with the NRP-A7 peptide. A group
of CD8  DCs was instead treated with CTLA-4–Ig (Fig. 8).
Contrary to the effects of IFN-  alone, cotreatment with the
PI3K inhibitor fully rescued the tolerogenic potential of
CD8  DCs, thus mimicking the activity of CTLA-4–Ig.
Effect of CTLA-4–Ig on Regulatory Mechanisms of FOXO3a
Expression. Although the molecular targets of PI3K ap-
pear to be multiple, many functional effects of PI3K acti-
Figure 7. Ability of CTLA-4–Ig or a PI3K inhibitor to activate FOXO
as revealed by different assays. (A) CTLA-4–Ig regulates FOXO expression.
Cytoplasmic and nuclear extracts from CD8  DCs of prediabetic mice
were subjected to immunoblot analysis for FOXO3a protein expression.
Cells were either untreated (time 0) or treated with CTLA-4–Ig for dif-
ferent times (indicated). The analysis was also conducted on NIH/3T3
cell immunoprecipitates (IP) obtained with control ( ) or FOXO3a-
specific antibody ( ). Controls for fractionation included the use of anti-
bodies specific for the cytosolic marker aldolase and the nuclear marker
lamin. These antibodies nonspecifically reacted with the heavy chain of
the Igs used for immunoprecipitation of NIH/3T3 cells. One experiment
representative of three is shown. (B) CTLA-4–Ig and the PI3K inhibitor
activate FOXO-dependent transcription in DCs. CD8  DCs purified
from prediabetic NOD female mice were transfected with pRL-TK in
combination with FHRE-Luc. After 24 h, cells were incubated with
CTLA-4–Ig or the PI3K inhibitor LY294002. Luciferase activity was
monitored at 6 and 24 h. Results are expressed as fold induction (mean  
SD of three independent experiments) of the sample incubated with
CTLA-4–Ig or LY294002 versus the corresponding untreated sample, the
control value being 1. Also reported in B are values of luciferase activity
in siRNA-treated DCs in which the FOXO3a gene had been silenced. In
mock-transfected DCs (i.e., cells treated with DOTAP alone), the fold
induction at 24 h of CTLA-4–Ig treatment was 2.4   0.3. (C) siRNA-
FOXO3a inhibits tryptophan catabolism in DCs treated with CTLA-4–Ig.
CD8  DCs from early prediabetic female mice, either mock-transfected
(DC) or treated with siRNA-FOXO3a (DC/siRNA), were exposed
overnight to CTLA-4–Ig, and kynurenine levels were measured in super-
natants. One experiment representative of two is shown. (D) siRNA-
FOXO3a inhibits the tolerogenic potential conferred by CTLA-4–Ig on
DCs. Combinations of CD8  DCs (either mock or siRNA-FOXO3a
transfected) and IL-12–treated CD8  DCs were loaded with NRP-A7
and injected into recipient mice to be assayed at 2 wk for skin test reactivity.
Either type of CD8  DC was used after control or CTLA-4–Ig treatment.
*, P   0.001, experimental versus control footpads. One experiment is
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vation are thought to be mediated by the serin/threonin
kinase AKT/PKB. Critical in attenuation of PI3K signal-
ing is dephosphorylation of the lipid products generated by
PI3K by the phosphatase and tensin homologue, PTEN, a
phosphoinositide phosphatase (13–15, 40). Therefore, we
became interested in ascertaining whether CTLA-4–Ig ef-
fects on FOXO might involve interference with positive
(e.g., PTEN-mediated) or negative (e.g., AKT-mediated)
regulation of FOXO activity. We performed immunoblot
analysis of PTEN expression in DCs from NOD female
mice of 4 versus 8 wk of age, either as such or after stimu-
lation with CTLA-4–Ig in vitro (Fig. 9 A). The results
showed that early prediabetic female mice displayed im-
paired expression of PTEN, a defect that was neverthe-
less rectified by CTLA-4–Ig. This suggested that unre-
strained PI3K signaling might occur in prediabetic mice.
We examined AKT phosphorylation in those animals
under different experimental conditions, namely after
treatment with IFN-  or combinations of IFN-  with
CTLA-4–Ig or LY294002. We also assessed FOXO3a
phosphorylation in the same samples. For comparison,
we analyzed phosphorylation of AKT and FOXO3a in
8-wk-old female mice. Fig. 9 B shows that marked phos-
phorylation of AKT and FOXO3a was observed in early
prediabetic mice in response to IFN- . However, co-
treatment with CTLA-4–Ig or LY294002 negated the ef-
fect of IFN- .
Discussion
In addition to DCs (41), CD4  CD25  regulatory T cells
are essential in the protection from organ-specific autoim-
mune diseases. In the pancreas, they inhibit actions of au-
toreactive T cells and thereby prevent diabetes progression.
Environmental stimuli can regulate the size of the intraislet
CD4  CD25  T cell pool (42). Regulatory T cells express
surface CTLA-4, and both cell-bound (9) and soluble
CTLA-4 (8) can signal DCs through B7 molecules to ini-
tiate the immunosuppressive pathway of tryptophan catab-
olism. Therefore, it is of interest that reduced expression of
CTLA-4 has been observed in NOD mice (2), that a defect
in tryptophan catabolism impairs tolerance in those animals
(12), and that CTLA-4–Ig (5) as well as regulatory T cells
(43–45) will protect susceptible hosts from diabetes devel-
opment. Recombinant IFN-   is also protective, either
when administered to diabetic mice (7) or when used to
condition DCs in vitro before transfer into prediabetic re-
cipients (6). However, cell signaling by IFN-  is compro-
mised in prediabetic NOD female mice, owing to per-
oxynitrite-induced nitration of STAT1 (12). Because the
immunosuppressive effects of CTLA-4–Ig in conventional
strains of mice require autocrine signaling by IFN-  (8, 9,
36), these data raise the question of whether modulation of
tryptophan catabolism contributes to the therapeutic effi-
cacy of CTLA-4–Ig in prediabetes.
Figure 8. IFN-  in combination with a PI3K inhibitor can induce tol-
erizing properties in CD8  DCs from early prediabetic NOD female
mice. Combinations of CD8  and IL-12–treated CD8  DCs were loaded
with NRP-A7 and injected into recipient mice to be assayed at 2 wk for
skin test reactivity. CD8  DCs were used after exposure to IFN-  in the
presence or absence of LY294002. In an alternative, CD8  DCs were
treated with CTLA-4–Ig. *, P   0.001, experimental versus control foot-
pads. One experiment is reported representative of three.
Figure 9. Effect of CTLA-4–Ig alone or in combination with IFN- 
on the expression of PTEN, AKT/phospho-AKT, and FOXO3a/phospho-
FOXO3a in early prediabetic NOD female mice. (A) Defective PTEN
expression and reversal by CTLA-4–Ig in 4-wk-old mice. CD8  DCs
from female donors of different ages were treated overnight with CTLA-4–Ig
before Western blot analysis. PTEN expression was investigated with a
specific monoclonal antibody. Loading controls consisted of samples re-
probed with   actin–specific antibody. One experiment representative of
three is shown. (B) Enhanced phosphorylation of AKT and FOXO3a in
response to a 30-min activation with IFN-  in the same cells as in A and
reversal by pretreatment with CTLA-4–Ig (18 h) or LY294002 (5 h).
CD8  DCs from 8-wk-old NOD females were used as control.Fallarino et al. 1059
In this study, we found that CTLA-4–Ig did induce
IFN- –dependent activation of IDO, thus implying effec-
tive autocrine signaling by the cytokine in DCs from early
prediabetic NOD female mice, in which IFN-  would be
ineffective per se. Because the signaling defect of recombi-
nant IFN-  was rectified by coexposure to an inhibitor of
peroxynitrite as well as a synthetic mimetic of SOD,
MnTBAP, we investigated whether CTLA-4–Ig might af-
fect the oxidant/antioxidant balance in target DCs. The re-
dox status of NOD mice is abnormal (46). SOD levels in
NOD female mice are extremely low, whereas in males,
values are considerably higher than in females but still
lower than in control mice (47). A metalloporphyrin-based
SOD mimetic inhibits adoptive transfer of autoimmune di-
abetes by a diabetogenic T cell clone (48). We found that
both MnTBAP and CTLA-4–Ig opposed the induction of
peroxynitrite by IFN-  in prediabetic mice. Moreover, a
SOD inhibitor was capable of blocking CTLA-4–Ig activ-
ity in CD8  DCs, leading to enhanced production of nitro-
tyrosine, reversal of the tolerogenic potential of those cells,
and impaired tryptophan catabolism. Thus, the ability of
CTLA-4–Ig to rescue CD8  DC function in NOD mice
was contingent on both the induction of autocrine IFN- 
and the oxygen-scavenging activity of SOD.
Transcriptional regulation of the murine inducible
SOD2 gene is complex, and multiple potential regulatory
elements are present for binding distinct classes of transcrip-
tion factors (49). The FOXO family of transcription factors
regulates expression of genes that have a prominent role in
the control of cell cycle, death, and metabolism (13, 14).
They represent important downstream targets of the PI3K
pathway, such that phosphorylation prevents their access to
the nucleus and inhibits expression of their function (15).
Much evidence is accumulating to indicate that unre-
strained PI3K signaling contributes to autoimmunity (40).
Among the genes regulated by FOXO factors is the SOD2
gene (19). Therefore, we wanted to investigate the effect of
CTLA-4–Ig or a PI3K inhibitor on SOD-mediated func-
tions in CD8  DCs from prediabetic mice. We found that
both agents were capable of activating FOXO-dependent
gene transcription in this DC subtype, and CTLA-4–Ig
modulated the cytoplasmic versus nuclear expression of
FOXO and induced SOD2 protein expression. At the same
time, the PI3K inhibitor allowed externally added IFN- 
to prime CD8  DCs for induction of tolerogenic effects.
On the other hand, silencing of the FOXO3a gene blocked
CTLA-4–Ig effects on CD8  DCs from prediabetic mice,
as demonstrated by assessment of tryptophan catabolism in
vitro and tolerogenic function in vivo. Thus, FOXO mod-
ulation by either CTLA-4–Ig or a PI3K inhibitor appears
to be a prerequisite for the occurrence of SOD-dependent
effects that will allow endogenous or external IFN-  to ini-
tiate tolerogenesis in CD8  DCs from prediabetic mice.
The mechanisms whereby CTLA-4–Ig, different from
IFN- , can activate FOXO are presently unclear. Recent
evidence indicates that CTLA-4 determines the unequal
resistance of Th1 and Th2 cells against activation-induced
cell death by a mechanism requiring PI3K function (50).
Activation of PI3K by receptor stimulation initiates events
leading to phosphorylation of AKT. Phosphorylated AKT
migrates into the nucleus and phosphorylates FOXO tran-
scription factors, resulting in nuclear exclusion and inhibi-
tion of transcription. The PI3K/AKT/FOXO signaling
module appears to be remarkably conserved during evolu-
tion. Although the regulation and function of FOXO ac-
tivity has been resolved in detail through genetic analysis in
the nematode worm Caenorhabditis elegans, in mammalian
cells, FOXO regulation and function have only recently
started to be explored. An important concept that has
emerged from several studies is that PTEN-mediated de-
phosphorylation of the lipid products generated by PI3K is
crucial in modulating PI3K signaling (13–15, 40). On ex-
amining phosphorylation of AKT and FOXO3a in NOD
mice, we observed marked phosphorylation of both in re-
sponse to IFN-  in early prediabetic mice, an effect that
was ablated by cotreatment with CTLA-4–Ig. Interest-
ingly, defective expression of PTEN was demonstrated in
those mice, and again the defect was rectified by CTLA-4–
Ig. Taken together, these data suggest that the effects of
CTLA-4–Ig on FOXO3a expression might involve inter-
ference with physiological regulators of FOXO factors. A
hypothetical model for the role of CTLA-4–Ig in correct-
ing the defect in tolerogenesis of NOD mice is depicted in
Fig. 10. Although the mechanisms of CTLA-4–Ig interfer-
ence with PTEN expression are presently unknown, it is
interesting to note that the genetic deficiency of either
CTLA-4 (51) or PTEN (40) results in a fatal lymphoprolif-
erative disease and/or development of autoimmunity.
In general, activation of FOXOs causes growth suppres-
sion in a variety of cell types, whereas in cells of the
immune system, most notably T cells, programmed cell
death is often induced (13). Therefore, the observation of
FOXO-dependent gene transcription by CTLA-4–Ig in
DCs is of interest, further suggesting that FOXO activation
results in cell type–specific gene regulation. In certain cells
of the immune system or under conditions in which a rapid
turnover of cells is required for homeostasis, the stress-induced
activation of FOXO factors may result in cell death. In con-
trast, in cells that are not continuously produced, or when a
critical function would be compromised by oxidative stress,
Figure 10. Hypothetical model for the
role of CTLA-4–Ig in correcting the defec-
tive tolerogenesis of early prediabetic NOD
female mice. CTLA-4–Ig may induce IFN- 
production in CD8  DCs and, at the same
time, enable cell responsiveness to the auto-
crine STAT1-dependent effects of the cyto-
kine, leading to activation of the tolerogenic
pathway of tryptophan catabolism. Al-
though aberrant peroxynitrite formation
would normally impede STAT1 phosphor-
ylation and IFN-  responsiveness in diabetes-prone animals (dotted line),
CTLA-4–Ig may reduce peroxynitrite formation via enhanced SOD2 ex-
pression. This, in turn, could result from increased activity of the tran-
scription factor FOXO3a, whose nuclear persistence is conditioned by
positive and negative regulators such as PTEN and phospho-AKT, both
of which appear to be affected by cell treatment with CTLA-4–Ig.CTLA-4–Ig Induces FOXO-dependent Transcription in NOD Mice 1060
FOXO activity will result in protection, for example by up-
regulation of oxidant-scavenging proteins (19).
The antecedent of diabetes in NOD mice is insulitis,
which begins in lymph nodes when   cell–specific T lym-
phocytes encounter APCs presenting   cell–derived pep-
tides. The stimulus initiating insulitis appears to be a ripple
of   cell death that occurs physiologically in juvenile mice
of all strains. Although the mechanisms whereby this event
results in induction of immunity rather than tolerance in
diabetes-prone NOD mice is unclear, an important ele-
ment could be represented by the recruitment and function
of CD8  DCs (52). Our current data are consistent with
the notion that changes in APCs underlie the initiation of
autoantigen exposure, and may provide some insight into
the nature of the imbalance between immunity and toler-
ance in the priming process. Aberrant IL-12 production
(53), potentiating immunity by CD8  DCs, and oxidative
stress (54), impairing tolerogenesis by CD8  DCs, may
combine with defective expression of regulatory T cell ac-
tivity (2) to swing the balance in favor of the immunogenic
presentation of autoantigens. Soluble CTLA-4 will oppose
oxidative stress not only by virtue of SOD2 induction, but
also by rescuing the activity of IDO, which uses super-
oxide anion as a substrate (11). Improved tolerogenesis re-
sulting from the antioxidant and IFN- –inducing abilities
of CTLA-4–Ig may thus skew DCs toward unresponsive-
ness to autoantigens.
In conclusion, the current data expand on our previous
hypothesis that a defect in tryptophan catabolism impairs
tolerance in NOD mice, provide new interpretive clues to
mechanisms of the beneficial action of CTLA-4–Ig in pre-
diabetic mice, and indicate that B7-mediated signaling in
DCs may lead to a multiplicity of downstream effects. Fur-
thermore, the new data reveal a role for FOXO factors in
regulating the redox status of DCs, and emphasize the im-
portance of oxidative stress in the pathogenesis of autoim-
munity in NOD mice. It is conceivable that experimental
studies targeting prediabetes by concordant actions on the
redox status of APCs and T cell regulation of APC func-
tion may provide a framework for the design of innovative
forms of immunomodulation in humans.
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